Evidence map›Paper›PMID 39956904›Full record

ReviewMicrobial cell factories2025

Enhancing recombinant growth factor and serum protein production for cultivated meat manufacturing.

Prashant Mainali, Melvin Shen-Wei Chua, Ding-Jie Tan, Bernard Liat-Wen Loo, Dave Siak-Wei Ow

Abstract readReview
In one paragraph

Review in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Prashant Mainali *Agency for Science, Technology and Research (A*STAR), Bioprocessing Technology Institute (BTI), 20 Biopolis Way, Centros #06-01, Singapore, 138668, Republic of Singapore.
Melvin Shen-Wei Chua *Agency for Science, Technology and Research (A*STAR), Bioprocessing Technology Institute (BTI), 20 Biopolis Way, Centros #06-01, Singapore, 138668, Republic of Singapore.
Ding-Jie TanAgency for Science, Technology and Research (A*STAR), Bioprocessing Technology Institute (BTI), 20 Biopolis Way, Centros #06-01, Singapore, 138668, Republic of Singapore.
Bernard Liat-Wen LooFood, Chemical and Biotechnology, Singapore Institute of Technology, 10 Dover Dr, Singapore, 138683, Republic of Singapore.
Dave Siak-Wei OwAgency for Science, Technology and Research (A*STAR), Bioprocessing Technology Institute (BTI), 20 Biopolis Way, Centros #06-01, Singapore, 138668, Republic of Singapore. dave_ow@bti.a-star.edu.sg.

Funding

Singapore Food Story (SFS) R&D Programme H20H8a0003Singapore Food Story (SFS) R&D Programme W22W3D0004Singapore Food Story (SFS) R&D Programme W23W2D0009
6 · The paper itself

Abstract

The commercial growth factors (GFs) and serum proteins (SPs) contribute to the high cost associated with the serum-free media for cultivated meat production. Producing recombinant GFs and SPs in scale from microbial cell factories can reduce the cost of culture media. Escherichia coli is a frequently employed host in the expression recombinant GFs and SPs. This review explores critical strategies for cost reduction in GFs and SPs production, focusing on yield enhancement, product improvement, purification innovation, and process innovation. Firstly, the review discusses the use of fusion tags to increase the solubility and yield of GFs & SPs, highlighting various studies that have successfully employed these tags for yield enhancement. We then explore how tagging strategies can streamline and economize the purification process, further reducing production costs. Additionally, we address the challenge of low half-life in GFs and SPs and propose potential strategies that can enhance their stability. Furthermore, improvements in the E. coli chassis and cell engineering strategies are also described, with an emphasis on the key areas that can improve yield and identify areas for cost minimization. Finally, we discuss key bioprocessing areas which can facilitate easier scale-up, enhance yield, titer, and productivity, and ultimately lower long-term production costs. It is crucial to recognize that not all suggested approaches can be applied simultaneously, as their relevance varies with different GFs and SPs. However, integrating of multiple strategies is anticipated to yield a cumulative effect, significantly reducing production costs. This collective effort is expected to substantially decrease the price of cultivated meat, contributing to the broader goal of developing sustainable and affordable meat.

Indexed as

Blood ProteinsIntercellular Signaling Peptides and ProteinsMeatRecombinant ProteinsAnimalsEscherichia coliIn Vitro MeatBlood ProteinsIntercellular Signaling Peptides and ProteinsRecombinant ProteinsBioprocess optimizationCell line engineeringCultivated meatEscherichia coliGrowth factor (GF) productionSerum protein (SP) production

Identifiers

PMID39956904
PMCPMC11831813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.